Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels

Overview

According to the World Health Organization (WHO), cardiovascular diseases are the worldwide leading cause of death. For the French public health, cardiovascular diseases are the leading cause of death for the women and the second for men. Each year in France, approximately 120,000 acute coronary syndromes (ACS) occur, including 60,000 myocardial infarctions and more than 15,000 deaths. To prevent or reverse this process, the WHO recommends early detection of the diseases and reduce behavioral and cardiovascular risk factors. For the patient, the European Society of Cardiology (ESC) recommends the implementation of secondary prevention measures, the lifestyle modifications and the encouragement to become an actor in the management of his health. The first year, the medical follow-up is recommended at 3, 6 and 12 months. Since 2019, in order to reduce the impact of LDL cholesterol, the ESC has recommended that LDL cholesterol levels be lower than 0.55 g/L accompanied by a reduction of at least 50% from their initial value. In 2023, it clarified this recommendation by recommending a laboratory reassessment within 4-6 weeks after hospital discharge. The application of these recommendations comes up against the difficulties of real life: 1. The increase in the number of elderly people and people with one or more chronic diseases; 2. In France, the significant regional disparities in the number of physicians; 3. In 2022, six months after hospitalization for an ACS, only 21.6% of French patients had benefited from a cardiac rehabilitation program; 4. Within 12 months of acute coronary syndrome, only 20% to 40% of patients achieved the LDL cholesterol targets recommended by the ESC. Given the difficulties in implementing the recommendations, investigators believe it is essential to rethink the care pathway for post-ACS patients. The investigator's hypothesis is that, in addition to the standard pathway, a care offering access to other healthcare professionals (advanced practice nurse, dietitian, pharmacist) should increase the proportion of patients achieving LDL cholesterol targets (LDL cholesterol \< 0.55 g/L and a 50% reduction in this level compared to the baseline value) at 12 months. LDL cholesterol was selected as the endpoint because it has been proven that a reduction in LDL cholesterol corresponds to a 22% reduction in cardiovascular events. To test this hypothesis, the investigators designed a multicenter controlled and randomized trial with two parallel arms: * "Routine Cares" arm: Each center will program cares as usual and will schedule patient follow-up according to their wishes (cardiac rehabilitation, visits to the general practitioner and/or cardiologist). * "Intervention" arm: In addition to routine care as described above, the patient will receive an interdisciplinary consultation one month after hospital discharge and three consultations with the IPA (3, 6, and 12 months). In order for the conclusions of this protocol to reflect French practices, it is planned to include 230 people who have presented with acute coronary syndrome in four healthcare facilities in France (both in Paris and outside Paris).

Interventions

• Behavioral "New" care pathway
  Initially, the patient will have an interdisciplinary consultation aimed at identifying personalized goals for the patient and providing educational/preventive care using tools that will be provided to all centers. This consultation will bring together a cardiologist, an advanced practice nurse (APN), a dietitian and a pharmacist. This consultation will take place approximately 4 weeks after the hospitalization for acute coronary syndrome (ACS). Secondly, the patient will have 3 follow-up consu
• Other "Standard" care pathway
  The French National Health Authority recommends two medical visits (at 6 and 12 month) and, if necessary, a third one (between the first and third month post-ACS) for the monitoring of the left ventricular. - The European Society of Cardiology recommends a reassessment of the lipid profile within 4-6 weeks post-ACS.

Primary outcome measures

• Proportion of patients reaching the LDL cholesterol target [Time frame: At enrollment then at the 12th month]

Secondary outcome measures (12)

• Proportion of patients reaching the LDL cholesterol target [Time frame: At enrollment then at the first month, 6th month and 12th month]
• Proportion of patients reaching the LDL cholesterol target [Time frame: At enrollment then at the first month, 6th month and 12th month]
• Changes in cardiovascular risk factors [Time frame: At enrollment then at the first month, 6th month and 12th month]
• Physical Activity Score [Time frame: At enrollment then at the 6th month and 12th month]
• Proportion of patients who participated in a cardiac rehabilitation program [Time frame: At 6th month and 12th month]
• Proportion of patients consuming toxic substances and their quantity measured [Time frame: At enrollment then at the 6th month and 12th month]
• Quality of life score [Time frame: At enrollment then at the 6th month and 12th month]
• Therapeutic Compliance Score [Time frame: At enrollment then at the 6th month and 12th month]
• List of lipid-lowering treatments taken by patients [Time frame: At enrollment then at the first month, 6th month and 12th month]
• Number of medical (cardiologist or general practitioner) and/or paramedical (dietician, etc.) consultations [Time frame: At 6th month and 12th month]
• Mortality rate and the reasons [Time frame: At 6th month and 12th month]
• Rehospitalization rates and the reasons [Time frame: At 6th month and 12th month]

Eligibility criteria

Inclusion criteria

• Adult patients hospitalized for ACS (ST+ or ST-), affiliated with a social security scheme, able to understand the protocol and having signed the study consent.

Exclusion criteria

• Patients with a complication of the ACS (mechanical complication, cardiogenic shock, very severe left ventricular dysfunction, presence of an intraventricular thrombus, complex ventricular rhythm disorder) ;
• Proven cognitive impairment or decompensated psychological/psychiatric disorder ;
• Any progressive inflammatory and/or infectious condition ;
• Any orthopedic problem precluding the physical activity ;
• Current participation in any clinical research project aimed at reducing LDL cholesterol levels ;
• Pregnant or breastfeeding woman ;
• Patient receiving state medical assistance ;
• Patient under guardianship or curatorship, or any other legal protection measure ;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Prevention

Study locations

France · 4 centers

• Centre Hospitalier Sud Francilien, Pôle Cardiologie — Corbeil-Essonnes
• Hopital Saint Joseph-Saint Luc, Cardiologie — Lyon
• CHU Montpellier - Hôpital Arnaud de Villeneuve, Cardiologie — Montpellier
• Hôpital Européen Georges Pompidou - AP-HP, Cardiologie — Paris

Identifiers

NCT: NCT07178444 · APHP240952 · 2025-A00698-41 · PHRIP-23-0025

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗